Methods: Patients were divided into two groups as control and study groups. Insulin was given to the patients in the study group. Blood samples were collected from all of the patients with 20 minutes intervals beginning at the preanesthesia period until the closure of the sternum and the last sample was taken in the intensive care unit. Glucose and leptin levels were recorded.
Results: In the study group 71 ± 12 units of insulin was given. Intraoperative hyperglycemia was present in both groups but in the study group the levels were lower. The difference between the values during and after cardiopulmonary bypass was statistically significant (p < 0.05). During the same process there was inverse correlation between glucose and leptin levels.
Conclusions: In this study we demonstrated that glucose levels are lowered by crystallized insulin application under hypothermic cardiopulmonary bypass. Furthermore as we estimated an inverse correlation between glucose and leptin we are convinced that leptin is one of the influential factors in the development of hyperglycemia under hypothermic cardiopulmonary bypass.
The role of insulin and insulin antagonist hormones (glucagon, epinephrine, norepinephrine and cortisol) in the development of hyperglycemia under hypothermic cardiopulmonary bypass (CPB) has been documented [1,2]. Leptin is another hormone discovered recently both in vivo and in vitro studies, and it is also effective in glucose metabolism [3-6]. Leptin is not only important in the regulation of food intake and energy balance, but it also functions as a metabolic and neuroendocrine hormone. It is especially involved in glucose metabolism, as well as in normal sexual maturation and reproduction [7]. While adipose tissue mediated leptin blockades insulin secretion at the pancreatic level, insulin increases leptin levels [3,4,6,8-10]. In this study we aimed to put forward the relation between glucose and leptin under hypothermic cardiopulmonary bypass and effect of insulin administered to achieve normoglycemia on glucose leptin levels.
After obtaining approval of the ethics committee of our institution and informed consent, 35 patients underwent CABG surgery. Patients with diabetes mellitus or requiring emergency surgery was excluded. Any patient exhibiting significant pulmonary, endocrine, metabolic or neurologic pathology was also excluded. All cardiac medications were continued until the day before s u rg e r y. Patients were randomly separated into two groups as the control (n = 20) and study groups (n = 15). In all patients, a baseline measurement of blood glucose and leptin levels was performed before induction of anesthesia and was continued to be measured in every 20 minutes until the sternal closure. Final samples were obtained in the intensive care unit and only normal saline was administered for perioperative and postoperative i.v. infusions in any phase of these operations. Intravenous insulin application started simultaneously with the induction of anesthesia in the study group and lasted with the closure of the sternum. We modified the insulin administration protocol of Chaney and coworkers [12] since they encountered hypoglycemia attacks and applied insulin as described in Table 1.
Anaesthesia Management
After pre-oxygenation, anaesthesia was induced with 0.3 mg/kg etomidate, 1mg/kg remifentanil and 0.15 mg/kg vecuronium. Maintenance of anaesthesia was obtained with 0.7-1% sevoflurane in 50% N2O + 50% O2 with a continuous infusion of remifentanil at 0.2-0.25 mg/kg/min until the beginning of CPB. During CPB remifentanil infusion was reduced to 0.1 mg/kg/min, inhalation anaesthesia was stopped and the patients lungs were allowed to deflate. After completion of CPB remifentanil infusion was continued at 0.2- 0.25 mg/kg/min and 0.7-1 % sevoflurane in 100% O2 without N2O was started.
Cardiopulmonary Bypass
All patients underwent coronary artery bypass surgery with CPB by using a roller pump (Stockert SIII, Munich, Germany) and disposable membrane oxygenator (Dideco D708, Mirandola, Italy). The system was primed with crystalloid solutions. Approximately 1500 cc of priming solution which usually consisted of 1000 cc Isolyte S and 500 cc gelatine (Gelafusine, Braun, Germany) was used for all patients. Unless the patients were anaemic, blood was generally not added to the system. The patientshaematocrit was kept in the range of 25-28%. During perfusion, additional perfusate (Ringer´s solution) was added when necessary to run the system safely. Activated clotting time (ACT) was maintained over 400 sec. Standard cardiopulmonary techniques were used during extracorporeal circulation.
Blood Sampling
Arterial blood samples were collected from the patients in every twenty minutes in six different phases of the operation; a) preinduction of anaesthesia, b) time between the entubation and CPB, c) cooling period during CPB, d) rewarming period during CPB and e) the time from the cessation of CPB to sternal closure, and f) in the intensive care unit were evaluated by taking the mean values.
Glucose measurement
Blood glucose levels were determined by blood glucose meter (Prestige and Prestige Smart System HDI Home Diagnostics, Inc. Ft. Landerdale, Florida, U.S.A.) Leptin measurement: Each sample was collected into a precooled tube, centrifuged at 4000 rpm for 2 min and serum was stored at 20°C. The levels of leptin were measured with a commercial enzyme-linked immunosorbent assay kit (Accucyte Human Leptin, European patent NO. EP 0 598 758 B1).
Statistics
SPSS 10.0 was used as the statistics program. Results are expressed as mean ± SD. A p value of < 0.05 is accepted to be statistically significant. We used the Student-t test and the Pearson´s correlation analysis tests for evaluation.
The levels of leptin were synchronously recorded and their progresswere found to be as follows; leptin: for phase (a) 7.9 ± 3.7 ng/mLversus 8.9 ± 3.5 ng/mL, phase (b) 5.4 ± 1.7 ng/mL versus 7.6 ± 2.3 ng/mL, phase (c) 5.0 ± 1.9 ng/mL versus 7.3±1.4 ng/mL, phase (d) 4.1 ± 1.9 versus 6.5 ± 1.3 ng/mL phase (e) 5.0 ± 2.3 ng/mL versus 8.8 ± 1.7 ng/mL and last phase (f) 5.9 ± 2.2ng/mL, 9.1 ± 1.1 ng/mL (Figure 2).
As the glucose levels in the control and study groups were compared before, during and after CPB periods it was found that before CPB glucose levels in the study group was low, but there was no statistically diferent from the control group; during the CPB and post CPB periods the glucose levels between the two groups turned out to be statistically significant (p < 0.05). When leptin values were evaluated it is seen that the difference in the control and study groups after the start of surgery was statistically significant (p < 0.05).
Analyzing the relation between leptin and glucose in the control and study groups with Pearson Correlation analysis test the results were found to be significant (p < 0.05) during intraoperative and postoperative periods (Figure 3).
In our study we found out that leptin levels are increased by insulin administration and a decrease in glucose levels is achieved therefore deducing that under hypothermic CPB a) there isnt a complete insulin resistance, b) the glucose metabolism still carries on and c) leptin is also effective in glucose metabolism. The inverse correlation we estimated between glucose and leptin in study and control groups indicates that in hyperglycemia that develops under hypothermic CPB leptin should also be taken into consideration.
1) Lehott JJ, Piriz H, Villard J, Cohen R, Guidollet J. Glucose homeostasis comparison between hypothermic and normothermic cardiopulmonary bypass. Chest 1992;102:106-11.
2) Kuntschen FR, Galetti PM, Hahn C. Glucose-insulin interactions during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1986;91:451-9.
3) Ceddia RB, William WN, Carpinelli AR, Curi R. Modulation of insulin secretion by leptin. General Pharmacology 1999;32:233-7.
4) Fehmann HC, Berghofer P, Brandhorst D, et al. Leptin inhibition of insulin secretion from isolated human islets. Acta Diabetol 1997;34:249-52.
5) Wellhoener P, Fruehwald-Schultes B, Kern W, et al. Glucose metabolism rather than insulin is a main determinant of leptin secretion in humans. J Clin Endocrinol Metab 2000;85:1267-71.
6) Widdup G, Bryson JM, Pawlak D, Phuyal JL, Denyer GS, Caterson ID. In vivo and in vitro suppression by leptin of glucose stimulated insulin hypersecretion in high glucosefed rats. Eur J Endocrinol 2000;143:431-7.
7) Wauters M, Considine RV, Van Gaal L F. Human leptin: From an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000;143:293-311.
8) Kolaczynski JW, Nyce MR, Considine RV, Boden G, Nolan JJ, Henry R. Acute and chronic effect of insulin on leptin production in humans studies in vivo and in vitro. Diabetes 1996;45:699-701.
9) Hardie L, Guilhot N, Trayhurn P. Regulation of leptin production in cultured mature white adipocytes. Hormone and Metabolic Research 1996;25:685-9.
10) Wabitsch M, Jensen PB, Blum WF, Chiristoffersen CT, Englaro P, Heinze E. Insulin and cortisol promote leptin production in cultured human fat cells. Diabetes 1996;45:1435-8.
11) Kain ZN, Zimolo Z, Heninger G. Leptin and the perioperative neuroendocrinological stress response. J Clin Endocrinol Metab 1999;84:2438-42.
12) Chaney MA, Nikolov MP, Blakeman BP, Bakhos M. Attempting to maintain normoglycemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycemia. Anesth Analg 1999;89:1091-5.
13) Cases JA, Gabriely I, Ma XH, et al. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo Diabetes 2001;50:348-52.